MB: Through a new boxed warning, FDA is alerting healthcare professionals about a subgroup of patients who cannot effectively metabolize the antiplatelet drug Plavix (clopidogrel). These patients, called "poor metabolizers", have little or no activity of the liver enzyme CYP2C19, which converts Plavix to its active form, and so they may not experience the full anti-clotting benefits of the drug.
AR: Practitioners should know that tests are available to identify genetic differences in CYP2C19 function, and thus identify poor metabolizers. They should consider using other antiplatelet medication or an alternative dosing strategy for these patients. And although raising the dose of Plavix in poor metabolizers can increase antiplatelet response, an appropriate dose regimen hasn't been established in a clinical trial.

标题
Reduced Effect from Plavix (FDA)

视频介绍
FDA Patient Safety News - June, 2010 - Show #99
FDA is alerting healthcare professionals through a new boxed warning about certain patients who cannot effectively metabolize the antiplatelet drug Plavix (clopidogrel).

Speaker #1: Mark Barnett (MB), Assistant Director, Education & Communication, U.S. Food and Drug Administration

Speaker #2: Anita Rayner (AR), Associate Director, Policy & Communications, U.S. Food and Drug Administration